Our Partnership Quality Survey, which provides insight and direction from our PAG partners, showed the positive results of our efforts. Overall satisfaction rose dramatically in 2025.
However, progress is still needed. According to one global Rare Disease patient organization, “a lot of improvement can be made in areas like contracts with patient associations. They must be easy to understand and applicable to our mutual engagement.”
90% Overall satisfaction with Sanofi’s approach to supporting patients
85% Respondents reporting Sanofi was doing “well or extremely well” on scientific exchange (vs 74% in 2024)
7% Increase in how partners perceive our understanding of patient experience (vs 2024)
STORY
Empowering patient-led data generation: the MPS Registry partnership
In 2025, we partnered with the National MPS Society to support development of a patient-controlled registry for mucopolysaccharidoses disorders. This innovative collaboration, publicly launched in February 2026, places data governance directly in the hands of patients and families, enabling individuals to contribute their health information to a platform they own and manage.
By providing initial sponsorship, Sanofi is helping create sustainable infrastructure that empowers the patient community to generate real-world data (RWD) on their own terms. This approach ensures data collection priorities reflect what matters most to those living with MPS, while providing researchers and regulators with valuable insights into disease progression and treatment outcomes.
“We are doing the hard work of meeting patients and caregivers where they are – in communities, in policy discussions, as advisors to our clinical trials, and throughout their journey through complicated healthcare systems. They have made us better for it, and we are proud of what we are building together.”
Géraldine, expert patient and mentor, France, living with COPD